Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage

Detalhes bibliográficos
Autor(a) principal: Boia, Raquel
Data de Publicação: 2017
Outros Autores: Elvas, Filipe, Madeira, Maria H., Aires, Inês D., Rodrigues-Neves, Ana C., Tralhão, Pedro, Szabó, Eszter C, Baqi, Younis, Müller, Christa E., Tomé, Ângelo R., Cunha, Rodrigo A., Ambrósio, Francisco, Santiago, Ana R.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/108124
https://doi.org/10.1038/cddis.2017.451
Resumo: Transient retinal ischemia is a major complication of retinal degenerative diseases and contributes to visual impairment and blindness. Evidences indicate that microglia-mediated neuroinflammation has a key role in the neurodegenerative process, prompting the hypothesis that the control of microglia reactivity may afford neuroprotection to the retina against the damage induced by ischemia-reperfusion (I-R). The available therapeutic strategies for retinal degenerative diseases have limited potential, but the blockade of adenosine A2A receptor (A2AR) emerges as candidate strategy. Therefore, we evaluated the therapeutic potential of a selective A2AR antagonist (KW6002) against the damage elicited by I-R. The administration of KW6002 after I-R injury reduced microglia reactivity and inflammatory response and afforded protection to the retina. Moreover, we tested the ability of caffeine, an adenosine receptor antagonist, in mediating protection to the retina in the I-R injury model. We demonstrated that caffeine administration dually regulated microglia reactivity and cell death in the transient retinal ischemic model, depending on the reperfusion time. At 24 h of reperfusion, caffeine increased microglial reactivity, inflammatory response and cell death elicited by I-R. However, at 7 days of reperfusion, caffeine administration decreased microglia reactivity and reduced the levels of proinflammatory cytokines and cell death. Together, these results provide a novel evidence for the use of adenosine A2AR antagonists as potential therapy for retinal ischemic diseases and demonstrate the effect of caffeine on the regulation of microglia-mediated neuroinflammation in the transient ischemic model.
id RCAP_c032029825e933380a93a4c0a7567e6d
oai_identifier_str oai:estudogeral.uc.pt:10316/108124
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damageAdenosineAdenosine A2 Receptor AntagonistsAnimalsCaffeineHumansInflammationIschemiaMaleMicrogliaNitrobenzenesPyridinesRatsReceptor, Adenosine A2AReperfusion InjuryRetinaRetinal DiseasesTransient retinal ischemia is a major complication of retinal degenerative diseases and contributes to visual impairment and blindness. Evidences indicate that microglia-mediated neuroinflammation has a key role in the neurodegenerative process, prompting the hypothesis that the control of microglia reactivity may afford neuroprotection to the retina against the damage induced by ischemia-reperfusion (I-R). The available therapeutic strategies for retinal degenerative diseases have limited potential, but the blockade of adenosine A2A receptor (A2AR) emerges as candidate strategy. Therefore, we evaluated the therapeutic potential of a selective A2AR antagonist (KW6002) against the damage elicited by I-R. The administration of KW6002 after I-R injury reduced microglia reactivity and inflammatory response and afforded protection to the retina. Moreover, we tested the ability of caffeine, an adenosine receptor antagonist, in mediating protection to the retina in the I-R injury model. We demonstrated that caffeine administration dually regulated microglia reactivity and cell death in the transient retinal ischemic model, depending on the reperfusion time. At 24 h of reperfusion, caffeine increased microglial reactivity, inflammatory response and cell death elicited by I-R. However, at 7 days of reperfusion, caffeine administration decreased microglia reactivity and reduced the levels of proinflammatory cytokines and cell death. Together, these results provide a novel evidence for the use of adenosine A2AR antagonists as potential therapy for retinal ischemic diseases and demonstrate the effect of caffeine on the regulation of microglia-mediated neuroinflammation in the transient ischemic model.Springer Nature2017-10-05info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/108124http://hdl.handle.net/10316/108124https://doi.org/10.1038/cddis.2017.451eng2041-4889Boia, RaquelElvas, FilipeMadeira, Maria H.Aires, Inês D.Rodrigues-Neves, Ana C.Tralhão, PedroSzabó, Eszter CBaqi, YounisMüller, Christa E.Tomé, Ângelo R.Cunha, Rodrigo A.Ambrósio, FranciscoSantiago, Ana R.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-11T17:16:30Zoai:estudogeral.uc.pt:10316/108124Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:24:23.458468Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage
title Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage
spellingShingle Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage
Boia, Raquel
Adenosine
Adenosine A2 Receptor Antagonists
Animals
Caffeine
Humans
Inflammation
Ischemia
Male
Microglia
Nitrobenzenes
Pyridines
Rats
Receptor, Adenosine A2A
Reperfusion Injury
Retina
Retinal Diseases
title_short Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage
title_full Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage
title_fullStr Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage
title_full_unstemmed Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage
title_sort Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage
author Boia, Raquel
author_facet Boia, Raquel
Elvas, Filipe
Madeira, Maria H.
Aires, Inês D.
Rodrigues-Neves, Ana C.
Tralhão, Pedro
Szabó, Eszter C
Baqi, Younis
Müller, Christa E.
Tomé, Ângelo R.
Cunha, Rodrigo A.
Ambrósio, Francisco
Santiago, Ana R.
author_role author
author2 Elvas, Filipe
Madeira, Maria H.
Aires, Inês D.
Rodrigues-Neves, Ana C.
Tralhão, Pedro
Szabó, Eszter C
Baqi, Younis
Müller, Christa E.
Tomé, Ângelo R.
Cunha, Rodrigo A.
Ambrósio, Francisco
Santiago, Ana R.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Boia, Raquel
Elvas, Filipe
Madeira, Maria H.
Aires, Inês D.
Rodrigues-Neves, Ana C.
Tralhão, Pedro
Szabó, Eszter C
Baqi, Younis
Müller, Christa E.
Tomé, Ângelo R.
Cunha, Rodrigo A.
Ambrósio, Francisco
Santiago, Ana R.
dc.subject.por.fl_str_mv Adenosine
Adenosine A2 Receptor Antagonists
Animals
Caffeine
Humans
Inflammation
Ischemia
Male
Microglia
Nitrobenzenes
Pyridines
Rats
Receptor, Adenosine A2A
Reperfusion Injury
Retina
Retinal Diseases
topic Adenosine
Adenosine A2 Receptor Antagonists
Animals
Caffeine
Humans
Inflammation
Ischemia
Male
Microglia
Nitrobenzenes
Pyridines
Rats
Receptor, Adenosine A2A
Reperfusion Injury
Retina
Retinal Diseases
description Transient retinal ischemia is a major complication of retinal degenerative diseases and contributes to visual impairment and blindness. Evidences indicate that microglia-mediated neuroinflammation has a key role in the neurodegenerative process, prompting the hypothesis that the control of microglia reactivity may afford neuroprotection to the retina against the damage induced by ischemia-reperfusion (I-R). The available therapeutic strategies for retinal degenerative diseases have limited potential, but the blockade of adenosine A2A receptor (A2AR) emerges as candidate strategy. Therefore, we evaluated the therapeutic potential of a selective A2AR antagonist (KW6002) against the damage elicited by I-R. The administration of KW6002 after I-R injury reduced microglia reactivity and inflammatory response and afforded protection to the retina. Moreover, we tested the ability of caffeine, an adenosine receptor antagonist, in mediating protection to the retina in the I-R injury model. We demonstrated that caffeine administration dually regulated microglia reactivity and cell death in the transient retinal ischemic model, depending on the reperfusion time. At 24 h of reperfusion, caffeine increased microglial reactivity, inflammatory response and cell death elicited by I-R. However, at 7 days of reperfusion, caffeine administration decreased microglia reactivity and reduced the levels of proinflammatory cytokines and cell death. Together, these results provide a novel evidence for the use of adenosine A2AR antagonists as potential therapy for retinal ischemic diseases and demonstrate the effect of caffeine on the regulation of microglia-mediated neuroinflammation in the transient ischemic model.
publishDate 2017
dc.date.none.fl_str_mv 2017-10-05
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/108124
http://hdl.handle.net/10316/108124
https://doi.org/10.1038/cddis.2017.451
url http://hdl.handle.net/10316/108124
https://doi.org/10.1038/cddis.2017.451
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2041-4889
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134129100423168